Results from a recent ESMO (European Society for Medical Oncology) and EURACAN (European Reference Network to Cancers) had led to a "call for policy action to standardize care pathways for rare cancers after analysis links guidance adherence to patient survival"). According to the survey, conducted between September - October 2025, patients with rare malignancies equate to 650,000 new cases per year, representing 24% if all cancer diagnoses across Europe.
ESMO and EURACAN thus propose the following actions:
- Centralize rare cancer surgeries in accredited centres
- Enforce mandatory multidisciplinary decision-making and time-critical standards throughout patient diagnosis, treatment, and follow-up
- Track adherence to established Clinical Practice Guidelines via national dashboards
Click here to learn more
Standardising care pathways for rare cancers through guideline adherence makes sense when 650,000 new cases a year are spread across many small populations. Centralised surgery, multidisciplinary decisions and tracked adherence are practical steps, not abstract policy. Following how oncbrothers cover guideline changes is useful here, because rare cancer care improves when community teams know exactly which pathway to follow and where to refer.
ReplyDeleteThe 650,000 figure really puts it in perspective — rare cancers are individually rare but collectively a quarter of all cancer diagnoses, so "rare" is a misleading label for the system burden. Of the three proposed actions, tracking guideline adherence through national dashboards feels like the one that would actually change behavior, since you cannot improve what you do not measure. Centralizing surgery in accredited centres makes obvious sense for volume-outcome reasons too.
ReplyDelete